(%)
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
- Ownership
-
Taysha Gene Therapies, Inc. Executive Compensation
* In original currency USD
Loading Data
|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total Amount |
|---|---|---|---|---|---|---|---|---|
| Monday, April 21st, 2025 | 2024 | Sean Nolan Chief Executive Officer and Director | 621,000 | 0 | 2,025,816 | 409,860 | 774 | 4,727,861 |
| Monday, April 21st, 2025 | 2023 | Sukumar Nagendran, M.D. President and Head of Research and Development | 565,000 | 0 | 0 | 254,250 | 1,344 | 1,248,120 |
| Monday, April 21st, 2025 | 2024 | Sukumar Nagendran, M.D. President and Head of Research and Development | 584,775 | 0 | 1,476,785 | 321,626 | 774 | 3,601,660 |
| Monday, April 21st, 2025 | 2023 | Kamran Alam Chief Financial Officer | 413,751 | 0 | 0 | 148,950 | 10,661 | 975,401 |
| Monday, April 21st, 2025 | 2024 | Kamran Alam Chief Financial Officer | 455,126 | 0 | 1,009,606 | 210,942 | 10,620 | 2,518,777 |
| Monday, April 21st, 2025 | 2023 | Sean Nolan Chief Executive Officer and Director | 600,000 | 0 | 0 | 324,000 | 1,331 | 1,522,515 |
| Thursday, April 18th, 2024 | 2022 | Sukumar Nagendran, M.D. President and Head of Research and Development | 23,542 | 0 | 0 | 0 | 54,093 | 1,363,545 |
| Thursday, April 18th, 2024 | 2023 | Sean Nolan Chief Executive Officer and Director | 600,000 | 0 | 0 | 324,000 | 1,331 | 1,522,515 |
| Thursday, April 18th, 2024 | 2022 | Sean Nolan Chief Executive Officer and Director | 25,000 | 0 | 0 | 0 | 74,000 | 1,899,276 |
| Thursday, April 18th, 2024 | 2023 | Kamran Alam Chief Financial Officer | 413,751 | 0 | 0 | 148,950 | 10,661 | 975,401 |
| Thursday, April 18th, 2024 | 2022 | Kamran Alam Chief Financial Officer | 401,700 | 156,000 | 0 | 136,578 | 9,330 | 1,201,823 |
| Thursday, April 18th, 2024 | 2023 | Sukumar Nagendran, M.D. President and Head of Research and Development | 565,000 | 0 | 0 | 254,250 | 1,344 | 1,248,120 |
| Monday, May 8th, 2023 | 2022 | Sukumar Nagendran, MD President and Head of Research and Development | 23,542 | 0 | 0 | 0 | 54,093 | 1,363,545 |
| Monday, May 8th, 2023 | 2021 | RA Session II Former President, Chief Executive Officer and Director | 542,800 | 0 | 0 | 0 | 150 | 4,571,200 |
| Monday, May 8th, 2023 | 2022 | Kamran Alam Chief Financial Officer | 401,700 | 156,000 | 0 | 136,578 | 9,330 | 1,201,823 |
| Monday, May 8th, 2023 | 2021 | Kamran Alam Chief Financial Officer | 390,000 | 0 | 0 | 0 | 5,515 | 1,807,521 |
| Monday, May 8th, 2023 | 2022 | Sean Nolan Chief Executive Officer and Director | 25,000 | 0 | 0 | 0 | 74,000 | 1,899,276 |
| Monday, May 8th, 2023 | 2022 | RA Session II Former President, Chief Executive Officer and Director | 537,939 | 271,400 | 0 | 0 | 173 | 1,963,202 |
| Thursday, April 28th, 2022 | 2020 | RA Session II President, Chief Executive Officer and Director | 362,594 | 0 | 4,060,626 | 271,878 | 154 | 4,695,252 |
| Thursday, April 28th, 2022 | 2021 | RA Session II President, Chief Executive Officer and Director | 542,800 | 0 | 0 | 0 | 150 | 4,571,200 |
| Thursday, April 28th, 2022 | 2020 | Suyash Prasad, M.B.B.S, F.F.P.M. Chief Medical Officer and Head of Research and Development | 216,833 | 0 | 3,668,409 | 129,975 | 152 | 4,015,369 |
| Thursday, April 28th, 2022 | 2021 | Suyash Prasad, M.B.B.S, F.F.P.M. Chief Medical Officer and Head of Research and Development | 432,600 | 0 | 0 | 181,692 | 3,051 | 2,231,064 |
| Thursday, April 28th, 2022 | 2020 | Kamran Alam Chief Financial Officer | 142,088 | 0 | 4,933,703 | 85,217 | 330,153 | 5,491,161 |
| Thursday, April 28th, 2022 | 2021 | Kamran Alam Chief Financial Officer | 390,000 | 0 | 0 | 0 | 5,515 | 1,807,521 |
